Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Migraine Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2015
Price : $35 *
At a glance
- Drugs AMG 333 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Amgen
- 29 Jan 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 16 Oct 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.